

Krishna Institute of Medical Sciences (KIMS IN)

Q1FY27 Result Update

August 05, 2026

☒ Estimate Change | ☒ Target | ☐ Reco.

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	BUY		BUY	
Target Price	850		800	
Sales (INR mn)	51,110	61,522	50,589	60,102
% Chng.	1.0	2.4		
EBITDA (INR mn)	10,626	13,942	10,826	13,992
% Chng.	(1.8)	(0.4)		
EPS (INR)	7.4	13.0	8.9	14.1
% Chng.	(16.9)	(7.8)		

Key Data

KRII.BO | KIMS IN

BSE Code	543308
NSE Code	KIMS
52-W High / Low	INR 858 / INR 575
Face Value	2
Sensex / Nifty	78,429 / 24,615
Market Cap	INR 334 bn / \$ 3,505 mn
Shares Outstanding	420.01 mn
3M Avg. Daily Value	INR 567.22 mn

Shareholding Pattern (%)

Promoters	32.50
FII's	14.74
Mutual Funds	28.52
Domestic Institutions	5.91
Public & Others	18.33
Promoter's Pledge (INR bn)	11.15

Stock Performance (%)

	1M	3M	6M	12M
Absolute	(6.4)	16.5	30.5	6.5
Relative	(7.2)	14.8	39.5	10.0

Key Financials - Consolidated

Y/e Mar	FY25	FY26	FY27E	FY28E
Sales (INR mn)	30,351	39,046	51,110	61,522
EBITDA (INR mn)	7,829	8,020	10,626	13,942
Margin (%)	25.8	20.5	20.8	22.7
PAT (INR mn)	3,737	2,526	3,119	5,485
EV (INR mn)	339,585	353,164	352,674	350,450
Total Debt (INR mn)	19,109	32,440	21,190	18,690
C&C Eq. (INR mn)	805	747	6,005	6,079
EPS (INR)	9.3	6.3	7.4	13.1
Gr. (%)	20.5	(32.4)	17.6	75.8
DPS (INR)	-	-	-	2.3
Yield (%)	-	-	-	0.3
RoE (%)	18.8	11.5	9.7	12.4
RoCE (%)	17.5	10.9	11.3	15.0
EV/Sales (x)	11.2	9.0	6.9	5.7
EV/EBITDA (x)	43.4	44.0	33.2	25.1
PE (x)	85.2	126.0	107.2	60.9
P/BV (x)	14.9	14.2	7.9	7.2

New unit's ramp up remains on track

Quick Pointers

- Thane & Electronic City to breakeven in 1-2 quarters
- Net debt stands at Rs24bn as of July'26

Krishna Institute of Medical Sciences (KIMS) reported 16% YoY EBITDA growth, in line with our estimates; aided by reduced losses from Bengaluru units. The turnaround time for greenfield units in new clusters has been impressive and thereby demonstrates strong execution. New leadership team hiring across Karnataka and Kerala provides comfort for faster ramp-up in these clusters. Given its lean cost structure and partnership with local doctors/ leadership outside Andhra Pradesh (AP) and Telangana, we remain confident of achieving faster breakeven and +25% OPM across Maharashtra, Karnataka and Kerala clusters over the next 3-4 years. Our FY27E and FY28E EBITDA broadly remain unchanged however PAT stands reduced by 3-13% due to higher depreciation and interest charges. We expect 32% EBITDA CAGR over FY26-28E. Maintain 'Buy' rating with TP of Rs850/share based on 30x FY28E EV/EBITDA.

In line EBITDA; Bengaluru unit losses reduced by INR 206mn QoQ: KIMS reported EBITDA of INR 2.23bn; up 16% YoY; we estimated at INR 2.16bn. OPM declined by 30bps QoQ to ~19%; due to losses from new units. Telangana cluster adjusted for other income reported 11% YoY growth in EBITDA with OPM declined by 100bps YoY to 27.6%. as additional beds at Kondapur unit got commercialized in this quarter. AP units grew by 12% YoY with OPM of 21.3% (down 100 bps YoY). Maharashtra cluster reported INR 1.5bn (INR1.4bn QoQ) of revenues and INR 113mn positive EBITDA (INR 69mn QoQ). Growth was aided by Nagpur unit (EBITDA up 46% YoY) while losses from Thane unit remain flat QoQ at INR 79mn. The combined units at Bangalore reported INR 810mn of revenues with EBITDA loss of INR 192mn in Q1 (INR 398mn QoQ). Kerala cluster reported EBITDA of INR 75mn vs INR 99mn in Q4. PAT came in lower at INR 415mn; down 47% YoY; below our estimates; impacted by higher interest and depreciation charges.

Strong ARPOB; occupancy declines due to new bed addition: Revenues grew 35% YoY to Rs 11.8bn, slightly ahead of our estimates led by strong ARPOB growth across the clusters. KIMS consol occupancy (on operational beds) was at 49% in Q1 vs 52.5% in Q4. In Q1, KIMS added 208 beds at Palakkad and 587 beds at Kondapur. Consolidated ARBOB improved 10% YoY to INR 47.2k/day in Q1. For Q1FY27, there was a reduction in ALOS to 3.47 days from 3.56 days in Q1FY26. IP/OP volumes grew by 27%/31% YoY in Q1.

Quarter Summary

Y/e Mar	Q1'27E	Q1'27A	% Var.	Q1'26A	YoY gr. (%)
Net Sales (INR mn)	11,124	11,795	6.0	8,716	35.0
EBITDA (INR mn)	2,169	2,234	3.0	1,926	16.0
Margin (%)	19.5	18.9	-60 bps	22.1	-320 bps
PAT (INR mn)	606	415	-32.0	786	-47.0

Source: Company, PL

Param Desai
 paramdesai@plindia.com | +91-22-66322259

Sanketa Kohale
 sanketakohale@plindia.com | +91-22-66322426

Dev Kothari
 devkothari@plindia.com | +91-22-66322222

Conference Call Highlights

Bed expansion Plans: Telangana's operational bed capacity stood at 2,669 beds, including ~450 beds added (operational for 10 days in Q1) at Kondapur. Additional 40 beds were added at Mahadevapura, Bangalore unit (170 beds earlier to 210 beds) during Q1. ~200 Secunderabad beds remain temporarily non-operational until the replacement hospital is commissioned by end-CY27. Thrissur (O&M) is scheduled for commissioning over the next 3–4 months, while the Rajahmundry II greenfield project is under construction with INR600–750mn FY27 capex. Management reiterated its expansion focus on core markets (Maharashtra, Kerala, Telangana and Andhra Pradesh (primarily acquisition-led) and Karnataka (greenfield-led)); targeting 300–350 bed hospitals with scalability of ~100 additional beds. Brownfield opportunities have been identified across Kerala, Telangana and Maharashtra.

Capex & QIP proceedings: The company raised INR15bn through QIP, with INR11–11.25bn already utilized for debt repayment. The INR6bn promoter preferential allotment has been approved (25% upfront; balance over 18 months). Q1 capex stood at INR600–750mn, with capex of INR1–1.25bn guided over the next nine months for Secunderabad, Rajahmundry and residual Kondapur, excluding future project announcements. Maintenance capex is guided at ~INR1bn p.a. over the next 3–4 years. Management aims to maintain a 2.5x debt-equity ratio, with ~INR20bn+ of operating cash flows over the next 3–4 years primarily funding greenfield expansion in core clusters.

New units & guidance: New hospitals continue to scale up, with **Nasik** achieving EBITDA breakeven in Q1 and **Mahadevapura** (Bengaluru) turning EBITDA positive in June, supported by ~INR200mn revenue in July. **Electronic City** (Bengaluru) is expected to achieve breakeven over the next 1–2 quarters, with management targeting the Bengaluru cluster to be EBITDA-neutral in FY27. **Thane** witnessed a seasonally weak Q1 amid delayed insurance empanelments; however, post GIPSA approval in May, July revenue improved to INR210mn (vs. INR160mn in Q1) with ~10% EBITDA margin, and management expects Q2 breakeven if the current trajectory sustains. Insurance empanelment across the new hospitals is ~50% complete, with the balance expected by end-August/mid-September.

Telangana: The new Kondapur hospital (commissioned on 20 June) reported 30–40% MoM revenue growth in July, reaching a ~INR450mn monthly run-rate versus INR320–330mn at the legacy facility. The old hospital will remain operational for ~6 months, incurring ~INR150–160mn of annualized rental and operating costs. Management expects Kondapur to scale to ~INR1bn monthly revenue over the next 4–5 years, driven by oncology and transplant programs, with 30–32% EBITDA margins at scale. Reported occupancy remains optically subdued due to ~200 non-operational Secunderabad beds and 450 newly added Kondapur beds; adjusted occupancy stands at ~61–65%, with a target of ~70% over 3–4 years. Management reiterated a 30–35% sustainable EBITDA margin target for the mature Telangana portfolio (Secunderabad and legacy Kondapur at 34–35%, Sunshine at 38–39% in Q4), with the blended margin expected to remain at 30–31% near term before reverting to the 30–35% range as new capacities mature.

AP: AP cluster saw a temporary QoQ ARPOB moderation from the ~INR27,000 run-rate due to seasonal case-mix, with management expecting Q2 recovery. The recent rollout of oncology services across most AP hospitals should support ARPOB growth, while management sees higher medium-term growth potential than Telangana, driven by lower historical penetration across Vijayawada, Guntur and Vizag.

Maharashtra: It continues to witness a slower ramp-up than the southern markets, reflecting longer doctor onboarding and the transition from part-time to full-time practice (as evidenced by Nagpur's 18–24 month stabilization period). Nagpur recorded its highest-ever monthly revenue of INR300mn in July, while Thane is showing a recovery following GIPSA empanelment. Management remains constructive on the cluster's long-term growth potential, although the ramp-up is expected to remain gradual as the market matures.

Karnataka: Management expects ARPOB to normalize to INR80,000–85,000 as insurance/corporate empanelments are completed and the case mix broadens. Doctor hiring for FY27 is largely complete, with incremental additions aligned to capacity ramp-up. The cluster is targeted to achieve EBITDA breakeven (zero losses) in FY27.

Kerala: It remains in the investment phase, with management guiding single-digit EBITDA margins in FY27, improving to mid-teens in FY28 and stabilizing at 20–22% over the next 2–3 years. The margin gap versus mature clusters is primarily due to higher rental costs (a ~4–5% margin drag) rather than demand-related issues. ARPOB remained stable QoQ, indicating healthy demand, while expansion continues with one hospital added last quarter and another scheduled for commissioning by year-end.

ARPOB guidance: overall, ARPOB guidance at 4–5%.

Net debt: It declined from INR32.5bn in Q4 to INR25.7bn in Q1, and further to ~INR24bn by early July following deployment of QIP proceeds toward debt repayment. The reduction in interest costs will begin reflecting in earnings from Q2FY27 onwards, as the debt repayment occurred after receipt of QIP funds on 24 June and was not captured in Q1 results.

Minority interest It stood at 10.5% for Q1. Management expects it to remain within the 10–15% range over the longer term.

Exhibit 1: Quarterly Estimates

(INR mn)	Q1FY27	YoY gr.	Q2FY27E	YoY gr.	Q3FY27E	YoY gr.	Q4FY27E	YoY gr.
Sales	11,795	35.3%	12,282	27.8%	11,997	20.2%	15,037	39.9%
EBITDA	2,234	16.0%	2,650	29.9%	2,700	35.7%	3,042	47.3%
Margin (%)	18.9%		21.6%		22.5%		20.2%	
Adj. PAT	415	-47.2%	795	18.3%	839	57.2%	1,070	100.4%

Source: Company, PL

Exhibit 2: Q1FY27 Result Overview (INR mn) – In line EBITDA

Y/e March	1QFY27	1QFY26	YoY gr. (%)	Q1FY27E	% Var.	4QFY26	QoQ gr. (%)	FY27E	FY26	YoY gr. (%)
Net Sales	11,795	8,716	35.3	11,124	6.0	10,746	9.8	51,110	39,046	30.9
COGS	2,447	1,840	33.0	2,447	(0.0)	2,328	5.1	11,244	8,089	39.0
% of Net Sales	20.7	21.1		22.0		21.7		22.0	20.7	
Staff Cost	2,126	1,510	40.8	1,713	24.1	1,799	18.2	8,862	6,817	30.0
% of Net Sales	18.0	17.3		19.7		16.7		17.3	17.5	
Other Expenses	4,988	3,440	45.0	4,795	4.0	4,554	9.5	20,378	16,120	26.4
% of Net Sales	42.3	39.5		55.0		42.4		39.9	41.3	
Total	9,561	6,790	40.8	8,955	6.8	8,681	10.1	40,484	31,026	30.5
EBITDA	2,234	1,926	16.0	2,169	3.0	2,065	8.2	10,626	8,020	32.5
Margins (%)	18.9	22.1		19.5		19.2		20.8	20.5	
Other Income	164	71	131.0	100	64.0	97	69.1	420	262	60.3
Interest	834	326	155.8	650	28.3	681	22.5	2,800	2,025	38.3
Depreciation	1,008	534	88.8	900	12.0	850	18.6	3,966	2,832	40.0
PBT	556	1,137	(51.1)	719	(22.7)	631	(11.9)	4,281	3,425	25.0
Provision for Taxation	192	287	(33.1)	183	4.7	217	(11.5)	1,092	919	18.8
Tax rate %	34.5	25.2		25.5		34.4		25.5	26.8	
PAT	364	850	(57.2)	536	(32.1)	414	(12.1)	3,189	2,506	27.3
Minority Interest/Share in associate	(51)	64	(179.7)	(70)	(27.1)	(120)	(57.5)	70	(20)	
EO Items	-	-		-		109		-	112	
Reported PAT	415	786	(47.2)	606	(31.5)	425	(2.4)	3,119	2,414	29.2

Source: Company, PL

Exhibit 3: Revenue growth across clusters led by strong ARPOB

Cluster wise revenues (INR mn)	FY25	FY26	Q1FY27
Telangana (incl. Sunshine)	19,392	22,158	6,071
% total	63.9	56.7	51.5
AP	8,108	9,496	2,634
% total	26.7	24.3	22.3
Maharashtra	2,365	4,654	1,504
% total	7.8	11.9	12.8
Kerala	486	1,713	776
% total	1.6	4.4	6.6
Bangalore		1,025	810
% total	0.0	2.6	6.9
Total	30,351	39,046	11,795


Source: Company, PL

Exhibit 4: xxx Margin remain flat QoQ

Cluster wise EBITDA (INR mn)	FY25	FY26	Q1FY27
Telangana (incl. Sunshine)	5,743	6,558	1,678
OPM (%)	29.6	29.6	27.6
AP	1,962	2,337	560
OPM (%)	24.2	24.6	21.3
Maharashtra	221	-43	113
OPM (%)	9.3	-0.9	7.5
Kerala	-97	78	75
OPM (%)	-20.0	4.6	9.7
Bangalore	-	-910	-192
OPM (%)	-	-88.8	-23.7
Total	7,829	8,020	2,234
Consol OPM (%)	25.8	20.5	18.9


Source: Company, PL

Exhibit 5: Margins declined YoY due to new beds additions



Source: Company, PL

Exhibit 6: Healthy ARPOB growth of 10% YoY



Source: Company, PL

Financials

Income Statement (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Net Revenues	30,351	39,046	51,110	61,522
YoY gr. (%)	21.5	28.6	30.9	20.4
Cost of Goods Sold	6,269	8,089	11,244	13,535
Gross Profit	24,082	30,957	39,866	47,987
Margin (%)	79.3	79.3	78.0	78.0
Employee Cost	4,995	6,817	8,862	10,191
Other Expenses	11,258	16,120	20,378	23,854
EBITDA	7,829	8,020	10,626	13,942
YoY gr. (%)	22.8	2.4	32.5	31.2
Margin (%)	25.8	20.5	20.8	22.7
Depreciation and Amortization	1,772	2,832	3,966	4,296
EBIT	6,057	5,188	6,661	9,646
Margin (%)	20.0	13.3	13.0	15.7
Net Interest	903	2,025	2,800	2,300
Other Income	319	262	420	450
Profit Before Tax	5,473	3,425	4,281	7,796
Margin (%)	18.0	8.8	8.4	12.7
Total Tax	1,433	919	1,092	1,988
Effective Tax Rate (%)	26.2	26.8	26.0	26.0
Profit After Tax	4,040	2,506	3,189	5,808
Minority Interest	303	6	96	348
Share Profit from Associate	-	26	26	26
Adjusted PAT	3,737	2,526	3,119	5,485
YoY gr. (%)	20.5	(32.4)	23.5	75.8
Margin (%)	12.3	6.5	6.1	8.9
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	3,845	2,414	3,119	5,485
YoY gr. (%)	24.0	(37.2)	29.2	75.8
Margin (%)	12.7	6.2	6.1	8.9
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	3,845	2,414	3,119	5,485
Equity Shares O/s (mn)	400	400	420	420
EPS (INR)	9.3	6.3	7.4	13.1

Source: Company, PL

Balance Sheet (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Non-Current Assets				
Gross Block	30,488	53,087	60,087	66,087
Tangibles	30,488	53,087	60,087	66,087
Intangibles	-	-	-	-
Acc: Dep / Amortization	7,823	10,655	14,621	18,917
Tangibles	7,823	10,655	14,621	18,917
Intangibles	-	-	-	-
Net Fixed Assets	22,665	42,432	45,466	47,171
Tangibles	22,665	42,432	45,466	47,171
Intangibles	-	-	-	-
Capital Work In Progress	19,572	17,345	17,345	17,345
Goodwill	3,386	3,386	3,386	3,386
Non-Current Investments	991	1,032	1,032	1,032
Net Deferred Tax Assets	131	594	594	594
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	640	969	1,120	1,348
Trade Receivables	3,954	5,542	6,721	8,091
Cash & Bank Balance	805	747	6,005	6,079
Other Current Assets	3,716	3,329	3,662	4,028
Total Assets	57,360	77,587	87,543	91,284
Equity				
Equity Share Capital	800	800	840	840
Other Equity	20,578	21,674	41,293	45,804
Total Networth	21,378	22,474	42,133	46,644
Non-Current Liabilities				
Long Term Borrowings	16,542	26,726	15,476	12,976
Provisions	-	-	-	-
Other Non Current Liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	2,567	5,714	5,714	5,714
Trade Payables	2,691	3,228	4,201	5,057
Other Current Liabilities	4,397	5,565	6,043	6,569
Total Equity & Liabilities	57,360	77,587	87,543	91,284

Source: Company, PL

Cash Flow (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
PBT	5,473	3,425	4,281	7,796
Add. Depreciation	1,772	2,832	3,966	4,296
Add. Interest	903	2,025	2,800	2,300
Less Financial Other Income	319	262	420	450
Add. Other	(868)	(1,931)	26	26
Op. Profit before WC Changes	7,280	6,351	11,072	14,418
Net Changes-WC	(29)	(324)	(212)	(582)
Direct Tax	(1,433)	(919)	(1,092)	(1,988)
Net Cash from Op. Activities	5,818	5,108	9,768	11,848
Capital Expenditures	(12,343)	(15,718)	(7,000)	(6,000)
Interest / Dividend Income	-	-	-	-
Others	1,181	1,201	-	-
Net Cash from Inv. Activities	(11,162)	(14,517)	(7,000)	(6,000)
Issue of Share Cap. / Premium	-	-	16,500	-
Debt Changes	7,938	13,290	(11,250)	(2,500)
Dividend Paid	-	-	-	(974)
Interest Paid	(903)	(2,025)	(2,800)	(2,300)
Others	(1,600)	(1,862)	40	-
Net Cash from Fin. Activities	5,435	9,403	2,490	(5,774)
Net Change in Cash	91	(6)	5,258	73
Free Cash Flow	(6,525)	(10,610)	2,768	5,848

Source: Company, PL

Quarterly Financials (INR mn)


Y/e Mar	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Net Revenues	9,607	9,977	10,746	11,795
YoY gr. (%)	23.6	29.2	34.8	35.3
Raw Material Expenses	1,952	1,969	2,328	2,447
Gross Profit	7,655	8,008	8,418	9,348
Margin (%)	79.7	80.3	78.3	79.3
EBITDA	2,040	1,989	2,065	2,234
YoY gr. (%)	(6.5)	6.3	4.3	16.0
Margin (%)	21.2	19.9	19.2	18.9
Depreciation / Depletion	661	787	850	1,008
EBIT	1,379	1,202	1,215	1,226
Margin (%)	14.4	12.0	11.3	10.4
Net Interest	450	568	681	834
Other Income	42	52	97	164
Profit before Tax	971	686	631	556
Margin (%)	10.1	6.9	5.9	4.7
Total Tax	248	167	217	192
Effective Tax Rate (%)	25.5	24.3	34.4	34.5
Profit After Tax	723	519	414	364
Minority Interest	51	(15)	(120)	(51)
Share Profit from Associate	-	-	-	-
Adjusted PAT	672	534	534	415
YoY gr. (%)	(37.4)	(39.8)	(41.3)	(47.2)
Margin (%)	7.0	5.4	5.0	3.5
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	669	534	425	415
YoY gr. (%)	(36.0)	(37.8)	(58.3)	(47.2)
Margin (%)	7.0	5.4	4.0	3.5
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	669	534	425	415
Avg. Shares O/s (mn)	400	400	400	420
EPS (INR)	1.7	1.3	1.1	1.0

Source: Company, PL

Key Financial Metrics

Y/e Mar	FY25	FY26	FY27E	FY28E
Per Share (INR)				
EPS	9.3	6.3	7.4	13.1
CEPS	13.8	13.4	16.9	23.3
BVPS	53.4	56.2	100.3	111.1
FCF	(16.3)	(26.5)	6.6	13.9
DPS	-	-	-	2.3
Return Ratio (%)				
RoCE	17.5	10.9	11.3	15.0
ROIC	10.7	6.8	8.2	11.3
RoE	18.8	11.5	9.7	12.4
Balance Sheet				
Net Debt : Equity (x)	0.9	1.4	0.4	0.3
Net Working Capital (Days)	23	31	26	26
Valuation (x)				
PER	85.2	126.0	107.1	60.9
P/B	14.8	14.1	7.9	7.1
P/CEPS	57.8	59.4	47.1	34.1
EV/EBITDA	43.3	44.0	33.1	25.1
EV/Sales	11.1	9.0	6.9	5.6
Dividend Yield (%)	-	-	-	0.2
FCFF Yield (%)	(2.1)	(3.4)	0.8	1.7
PEG Ratio	4.1	(3.9)	6.0	0.8

Source: Company, PL

Price Chart

Recommendation History

No.	Date	Rating	TP (INR)	Share Price (INR)
1	09-Jul-26	BUY	800	806
2	19-May-26	Buy	800	717
3	09-Apr-26	BUY	810	662
4	09-Feb-26	BUY	810	647
5	06-Jan-26	BUY	810	654
6	19-Dec-25	BUY	810	638
7	10-Nov-25	BUY	840	701
8	08-Oct-25	BUY	815	706
9	08-Aug-25	BUY	815	745
10	08-Jul-25	BUY	725	695

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (INR)	Share Price (INR)
1	Ajanta Pharma	BUY	3730	3436
2	Anthem Biosciences	Buy	850	779
3	Apollo Hospitals Enterprise	BUY	9350	8754
4	Aster DM Quality Care	BUY	800	780
5	Aurobindo Pharma	HOLD	1400	1557
6	Brigade Enterprises	BUY	785	503
7	Cipla	Accumulate	1450	1393
8	Divi's Laboratories	Accumulate	8600	8056
9	Dr. Reddy's Laboratories	Accumulate	1300	1183
10	Eris Lifesciences	BUY	1700	1425
11	Fortis Healthcare	BUY	1120	944
12	Global Health	BUY	1600	1406
13	HealthCare Global Enterprises	BUY	820	635
14	Indoco Remedies	Hold	325	225
15	Ipca Laboratories	Buy	1800	1762
16	J.B. Chemicals & Pharmaceuticals	Buy	2400	2135
17	Jupiter Life Line Hospitals	BUY	360	319
18	Krishna Institute of Medical Sciences	BUY	800	806
19	Lupin	Accumulate	2500	2459
20	Max Healthcare Institute	BUY	1175	1085
21	Narayana Hrudayalaya	BUY	2250	1979
22	Oberoi Realty	Accumulate	2100	1883
23	Prestige Estates Projects	BUY	1800	1595
24	Rainbow Children's Medicare	BUY	1900	1546
25	Sun Pharmaceutical Industries	BUY	2150	1991
26	Sunteck Realty	BUY	520	291
27	Torrent Pharmaceuticals	BUY	5500	4872
28	Zydus Lifesciences	Accumulate	1080	1148

PL's Recommendation Nomenclature (Absolute Performance)

BUY	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

Indian Clients

We/I Mr. Param Desai MBA Finance, Ms. Sanketa Kohale MBA Finance, Mr. Dev Kothari BSc. Finance, Passed CFA Level II Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

US Clients

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

Prabhudas Lilladher Pvt. Ltd.

Corporate Office: 6th Floor, Tower 2B South Annex, One World Centre, 841, Senapati Bapat Marg, Lower Parel, Mumbai - 400013

Registered Office: 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018

Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd, which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipients particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report.

PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report.

PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai MBA Finance, Ms. Sanketa Kohale MBA Finance, Mr. Dev Kothari BSc. Finance, Passed CFA Level II Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.